BackPhoenix Biotech Acquisition Overview

Phoenix Biotech Acquisition Long Term Debt

Phoenix Biotech Acquisition's long-term debt is $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00
100.00% YoYΔ $-218308.00 vs prior year quarter

Peer trimmed avg / median

Loading

Phoenix Biotech Acquisition Long Term Debt History

Loading

Phoenix Biotech Acquisition vs. peers: Long Term Debt Comparison

Loading

Phoenix Biotech Acquisition Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Phoenix Biotech Acquisition (PBAX) FAQ

As of the most recent data (June 2026), PBAX shows a long-term debt of $0. That compares with $220K in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PBAX's long-term debt is now $0 (was $220K) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Phoenix Biotech Acquisition is outperforming or lagging.

Tracking PBAX's long-term debt over time shows whether Phoenix Biotech Acquisition is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $220K in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Phoenix Biotech Acquisition's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $0) with ownership activity and broader fundamentals.